Newsfiscal.ai
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
· Published
Article summary
Avalo Therapeutics reported a third-quarter 2026 net loss of $18.9 million and provided updates on its clinical pipeline, including plans for a Phase 3 program for abdakibart.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…